Prosecution Insights
Last updated: November 20, 2026
Application No. 18/044,989

TOOLS & METHODS USEFUL FOR DETECTION OF LACTOSE INTOLERANCE AND USES THEREOF

Final Rejection §103§112
Filed
Mar 12, 2023
Priority
Sep 14, 2020 — EU 20195885.7 +1 more
Examiner
GOLDBERG, JEANINE ANNE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
None recorded (individual inventor: Percevent DUCREST)
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
383 granted / 839 resolved
-14.4% vs TC avg
Strong +41% interview lift
Without
With
+40.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
68 currently pending
Career history
927
Total Applications
across all art units

Statute-Specific Performance

§101
23.0%
-17.0% vs TC avg
§103
19.6%
-20.4% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 839 resolved cases

Office Action

§103 §112
DETAILED CORRESPONDENCE Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to the papers filed April 26, 2026. Currently, claims 1-14, 20-24 are pending. Claims 6-14, 20-24 have been withdrawn as drawn to non-elected subject matter. Election/Restrictions Applicant's election of Group I and -13910C/T in the paper filed December 29, 2025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Applicant added Claims 20-24 directed to methods. Methods were non-elected, therefore Claims 20-24 have been withdrawn. The requirement is still deemed proper and is therefore made FINAL. Priority This application is a 371 of PCT/EP2021/085058, filed September 13, 2021 and claims priority to EP 20195885.7, filed September 14, 2020. Drawings The drawings are acceptable. Claim Rejections - 35 USC § 112- Second Paragraph The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 15-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. A) Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5 are rejected under 35 U.S.C. 103 as being unpatentable over Carlos et al. (Biotechnology Reports, Vol 16, pages 21-25, 2017) in view of Jiang et al. (J. of Dairy Science, Vol. 103, Issue 5, Pages 4002-4012, May 2020) and Nguyen et al. (WO2018068064, April 12, 2018). Carlos teaches allele -specific LAMP for the lactose intolerance (-13910 C/T dpSNP rs4988235) SNP using Au-nanoprobes. Carlos teaches primers and probes for MCM6 SNP -13910C/T characterization in Table 1. PNG media_image1.png 180 528 media_image1.png Greyscale These primers and probes are identical to instant SEQ ID NO: 2, 11, 4, 1, and 3 of Table 1 (page 20 of the specification). Carlos teaches these AS-LAMP amplification and primer design were performed according to Notomi (page 23, col. 1). Carlos does not teach using a lateral flow immunoassay device or the LB biotin primer of SEQ ID NO: 5. However, Jiang teaches LAMP may be used on lateral flow device. Jiang illustrates the test strip for multiplex loop-mediated isothermal amplification (mLAMP) on lateral flow dipstick (LFD). Thus, the art teaches LAMP may be performed on lateral flow strips. Jiang teaches Anti-FITC, anti-dioxin antibodies on the detection region. Jiang teaches the labels may be Au-particles. PNG media_image2.png 500 708 media_image2.png Greyscale Moreover, Nguyen teaches a lateral flow rapid test strip (see Figure 1). Nguyen teaches these test strips have a sample pad, a conjugate pad, nitrocellulose membrane, backing card (i.e backing support), absorbent wick and cover tape (page 46, lines 26-30). Nguyen teaches the base substrate is a nitrocellulose member and onto which the capture antigens are immobilized (capture line or test line). Nguyen teaches rapid lateral flow assays are capable of detecting multiple analytes simultaneously on a single strip. Nguyen teaches peptides may be conjugated to a ligand (e.g. biotin) and complexed with labeled ligand receptor (e.g. streptavidin-colloidal gold)(page 28)(limitations of Claim 5). An antibody specific to the labeled antibody or a second labeled antibody can be used to product a control signal. Nguyen teaches the lateral flow devices are rapid diagnostic tests for detecting complexes (page 8). With respect to Claim 3, Nguyen teaches multiple test lines (namely allows up to 10 antigens may be evaluated in a single assay). Figure 2B illustrates multiple capture test reagents (namely 5). Therefore, it would have been prima facie obvious prior to the invention to have modified the LAMP detection method of the T allele (-13910 C/T) as taught by Carlos to use a lateral flow rapid test strip of Nguyen in view of Jiang. Jiang teaches LAMP methods may be performed on lateral flow sticks. mLAMP-LFD assays are rapid and efficient, user-friendly and point of care. Additionally, Nguyen teaches the lateral flow rapid test strip is rapid and allows for diagnostic testing. The ordinary artisan would have been motivated to use a lateral flow rapid test strip because it allows point of care analysis and does not require sophisticated machinery. With respect to SEQ ID NO: 5, it would have been prima facie obvious to have designed the Loop B (LB) primer between the B1c and B2 sequences. SEQ ID NO: 5 is located in Loop B and would have been a functional equivalent for the LB primer. Conclusion No claims allowable. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Duong et al. teaches Evaluation of LAMP technique for the diagnosis of genetic predisposition to lactose intolerance Loop-Mediated isothermal amplification detection of lactose intolerance (Revue Francophone des Laboratories, Vol. 2018, No. 504, pages 20-26, July-August 2018). Duong teaches using LAMP to detect rs4988235 (13910C>T). Duong does not teach the sequence for the primers. Abildgaard et al. (Clinica Chimica Acta, Vol. 482, pages 50-56, 2018) teaches lactase persistence genotyping on whole blood b LAMP and melting curve analysis. Abildgaard teaches LAMP amplification but does not provide the sequence for the primers. Augustine et al. (Biology, Vol. 9, No. 8, 2020) teaches LAMP is a rapid, sensitive, specific and cost-effective point of care test for COVID. Augustine teaches LAMP analysis on a lateral flow device. Becherer et al. (Anal. Methods, Vol. 12, pages 717-746, 2020) teaches LAMP analysis on lateral flow dipsticks (see 4.3.4.1. Figure 7). Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEANINE ANNE GOLDBERG whose telephone number is (571)272-0743. The examiner can normally be reached Monday-Friday 6am-3:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng (Winston) Shen can be reached on (571) 272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEANINE A GOLDBERG/Primary Examiner, Art Unit 1682 May 14, 2026
Read full office action

Prosecution Timeline

Mar 12, 2023
Application Filed
Nov 23, 2025
Response after Non-Final Action
Feb 02, 2026
Non-Final Rejection mailed — §103, §112
Apr 26, 2026
Response Filed
May 18, 2026
Examiner Interview Summary
May 18, 2026
Applicant Interview (Telephonic)
May 18, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760375
DETECTION OF TUMOR-DERIVED DNA IN CEREBROSPINAL FLUID
2y 4m to grant Granted Oct 13, 2026
Patent 12753443
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
3y 2m to grant Granted Oct 06, 2026
Patent 12738355
METHODS OF TREATING BREAST CANCER
3y 5m to grant Granted Sep 15, 2026
Patent 12729404
METHOD AND KIT FOR TESTING DRUG HYPERSENSITIVITY REACTIONS CAUSED BY SULFONAMIDE DERIVATIVE-BASED ANTIEPILEPTIC DRUG AND USE OF THE KIT
3y 6m to grant Granted Sep 08, 2026
Patent 12698539
COMPOSITIONS AND METHODS FOR THE DETECTION OF A CHROMOSOMAL TRANSLOCATION IN BRASSICA NAPUS
4y 4m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
86%
With Interview (+40.7%)
3y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 839 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month